webinar register page

Webinar banner
KOL Webinar on VIP152 for the Treatment of Hematologic and Solid Tumors, hosted by Vincerx
The event will feature a presentation by Key Opinion Leaders (KOLs) Ian Flinn, M.D., Ph.D. (Sarah Cannon Center for Blood Cancer), John Byrd, M.D. (The Ohio State University), and Howard "Skip" Burris III, M.D. (Sarah Cannon) who will discuss the CDK9 inhibitor landscape in hematologic and solid tumors. Drs. Flinn, Byrd, and Burris will be available to answer questions following the formal presentations.

Mar 5, 2021 12:00 PM in Eastern Time (US and Canada)

* Required information
Loading

By registering, I agree to the Privacy Statement and Terms of Service.

Register

Speakers

Ian Flinn, M.D., Ph.D.
@Sarah Cannon Center for Blood Cancer
Dr. Flinn, M.D., Ph.D. is an internationally recognized clinical investigator whose research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia. This research includes first in human to phase 3 trials with novel approaches such as immune effector cell therapies, inhibitors of the B cell receptor pathway, and BCL-2 inhibitors amongst others. He is an author of approximately 200 articles in journals such as the New England Journal of Medicine, Lancet, Journal of Clinical Oncology and Blood. Dr Flinn joined Tennessee Oncology and Sarah Cannon in 2006 and serves as Director of Lymphoma Research. In his role, he oversees lymphoma research throughout Sarah Cannon and its affiliates. Dr. Flinn also serves as the director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology.
John C. Byrd, M.D.
@The Ohio State University
John C. Byrd, M.D. John C. Byrd, M.D., is an internationally known researcher and clinical specialist in leukemia and other hematologic malignancies at Ohio State University’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, where he serves as Senior Advisor for Cancer Experimental Therapeutics. He is a Distinguished University Professor of Medicine and Medicinal Chemistry and holds the D. Warren Brown Chair in Leukemia Research. Dr. Byrd is also the Chief Medical Officer for BEAT AML.
Howard A. "Skip" Burris III, MD, FASCO, FACP
@Sarah Cannon
Howard A. "Skip" Burris III, MD, FASCO, FACP serves as President and Chief Medical Officer of Sarah Cannon, as well as the Executive Director, Drug Development for Sarah Cannon Research Institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology. Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first-in-human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved. In 1997, he established in Nashville the first community-based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts.